Previous 10 | Next 10 |
– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog’s Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercial...
– First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient setting BERKELEY HEIGHTS, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmac...
2023-11-15 12:32:14 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Cormedix Inc (NASDAQ: CRMD), SciSparc Ltd (NASDAQ: SPRC), Solid Biosciences Inc (NASDAQ: SLDB), Heron ...
CorMedix Inc. (NASDAQ: CRMD) is one of today's top gainers. The company's shares have moved 6.67% on the day to $3.2. CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disea...
2023-11-15 10:33:38 ET More on CorMedix CorMedix Inc. (CRMD) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on CorMedix Historical earnings data for CorMedix Financial information for CorMedix For further details see: CorMedi...
2023-11-14 21:55:11 ET CorMedix Inc. (CRMD) Q3 2023 Earnings Conference Call November 14, 2023, 04:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors Joseph Todisco - CEO Matt David - EVP and CFO Phoebe Mounts - EVP and General Counsel Confer...
2023-11-14 19:45:15 ET Image source: The Motley Fool. CorMedix (NASDAQ: CRMD) Q3 2023 Earnings Call Nov 14, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: CorMedix (CRMD) Q3 2023 Earnings Call Transcript
2023-11-14 17:54:03 ET Gainers: Solid Biosciences ( SLDB ) +34% . CorMedix ( CRMD ) +20% . Arcturus Therapeutics ( ARCT ) +14% . Frequency Electronics ( FEIM ) +8% . Collective Audience ( CAUD ) +7% . Lose...
2023-11-14 16:10:34 ET More on CorMedix Seeking Alpha’s Quant Rating on CorMedix Historical earnings data for CorMedix Financial information for CorMedix For further details see: CorMedix GAAP EPS of -$0.17 beats by $0.04
BERKELEY HEIGHTS, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for th...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...